Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0640

0.0%

3:22 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: boomertree2	3/21/2014 9:24:02 PM
	Read Replies (1) of 13111

Form 8-K for PROVECTUS BIOPHARMACEUTICALS, INC. 21-Mar-2014 Regulation FD Disclosure Item 7.01. Regulation FD Disclosure. On March 21, 2014, Provectus Biopharmaceuticals, Inc. submitted via overnight courier for Monday, March, 24, 2014 delivery an application to the Food and Drug Administration for Breakthrough Therapy Designation ("BTD") for its oncology drug PV-10 for the treatment of melanoma. I don't believe the FDA 60 day review period begins until the date FDA notifies Provectus they opened the BTD application.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next